Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor,
has been proposed to mitigate the cytokine storm syndrome associated with severe COVID …

Background COVID-19 is an ongoing threat to society. Patients who develop the most
severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has …

Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

Abstract Purpose Interleukin-6 (IL-6) levels discriminate between patients with mild and
severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a …

ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …

Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …